TITLE

Bevacizumab in Metastatic Breast Cancer: Ready for Prime Time?

AUTHOR(S)
Mandock, Katherine; Soefje, Scott A.; Adams, R.
PUB. DATE
December 2011
SOURCE
Journal of Hematology Oncology Pharmacy;Dec2011, Vol. 1 Issue 4, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the U.S. Food and Drug Administration's (FDA) decision to remove bevacizumab's current labeled indication for metastatic breast cancer (MBC). Postapproval trials required with the FDA approval for bevacizumab for treatment did not demonstrate an overall survival (OS) advantage. According to the authors, FDA's decision is correct.
ACCESSION #
73343889

 

Related Articles

  • Progression-free or overall… That is the question…. Gupta, Sudeep // Indian Journal of Medical & Paediatric Oncology;Oct-Dec2010, Vol. 31 Issue 4, p103 

    The author reflects on the progress of the drug bevacizumab developed by Genentech and Roche. He mentions the move of the U.S. Food and Drug Administration (FDA) in removing the metastatic breast cancer (MBC) indication from bevacizumab. He notes that the move of FDA is an effect of its Oncology...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;11/26/2011, Issue 1379, p2 

    The article reports on the withdrawal of the U.S. Food and Drug Administration's approval of the breast cancer indication for bevacizumab in November 2011.

  • FDA approves lapatinib plus letrozole for HER-2--positive, HR-positive, metastatic breast cancer.  // Hem/Onc Today;2/25/2010, Vol. 11 Issue 4, p1 

    The article reports on the approval issued by the U.S. Food and Drug Administration (FDA) for the use of combined lapatinib and aromatase inhibitor letrozole for hormone-receptor-positive Her-2 positive metastatic breast cancer.

  • FDA Sets Decision Date.  // Chain Drug Review;2/27/2012, Vol. 34 Issue 4, p50 

    The article reports that the U.S. Food and Drug Organization will review Genentech Inc.'s breast cancer drug.

  • Advisory panel votes down bevacizumab for metastatic breast cancer. Shafer, Emily // Hem/Onc Today;1/1/2008, Vol. 9 Issue 1, p6 

    The article reports on the 5-4 vote by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) that progression-free survival alone is not a measure of direct clinical benefit. The Committee claims that it should not be used as a basis for FDA approval of...

  • REDUCING THE REGULATORY ROLE OF THE FDA: PROMOTING PATIENT AUTONOMY TO CHOOSE AVASTIN AND OTHER CANCER DRUGS. RAY, SARA J. // Connecticut Law Review;Nov2012, Vol. 45 Issue 1, p319 

    On November 18, 2011, the Food and Drug Administration (FDA) revoked accelerated approval of the breast cancer indication for Avastin, a cancer drug manufactured by Genentech. The FDA claims that Avastin, when used to treat metastatic breast cancer, does not provide a benefit that justifies the...

  • FDA panel rejects bevacizumab for metastatic breast cancer.  // Hem/Onc Today;1/1/2008, Vol. 9 Issue 1, p1 

    The article reports that the Oncology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 5-4 that bevacizumab should not be approved for first-line treatment of metastatic breast cancer. The reason behind the decision was the presence of an increase in grade-three and...

  • Breast cancer indication for bevacizumab. Elliott, William T. // Neurology Alert;Sep2010 Pharmacology, p2 

    The article focuses on the recommendation of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory committee to remove the indication for breast cancer treatment in bevacizumab.

  • Recent Advances in Selective Estrogen Receptor Modulators for Breast Cancer. Tianlin Wang; Qidong You; Shu-gui Huang, Frank; Hua Xiang // Mini Reviews in Medicinal Chemistry;Sep2009, Vol. 9 Issue 10, p1191 

    Estrogen has important physiological effects on the growth and function of hormone-dependent tissues, and the link between estrogen and breast cancer has been deciphered at the end of the 20th century. Tamoxifen, one of the first generation selective estrogen receptor modulators (SERMs), has...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics